Jamie L. Karagianis

Eli Lilly and Company, USA

Jamie L. Karagianis earned his M.D. degree (1985) at Memorial University of Newfoundland and his fellowship in psychiatry in 1990. He worked for 14 years as Staff Psychiatrist for the Health Care Corporation of St. John’s, held various academic positions at Memorial University of Newfoundland, and managed a large practice of community-based and hospital-based patients with severe mental illnesses. He joined Eli Lilly Canada in January 2004, and moved to the US Affiliate of Lilly in 2010. Licensed in psychiatry by the Royal College of Physicians and Surgeons of Canada, Dr. Karagianis has served on many professional committees and boards including the Professional Advisory Board of the Schizophrenia Society of Newfoundland and Labrador. He is a member of the Editorial Board for the Open Journal of Psychiatry, and a peer reviewer for several other journals. Dr. Karagianis has designed and participated as a clinical investigator in a number of pharmacological studies of schizophrenia, depression, acute agitation, and functional outcomes of patients taking antipsychotics. Other areas of interest include borderline personality disorder, cognitive therapy, electroconvulsive therapy, and evidence-based medicine. He has 36 papers accepted or published in peer-reviewed journals including Schizophrenia Research, Canadian Journal of Psychiatry, American Journal of Psychiatry, Journal of Clinical Psychiatry, Neuropsychopharmacology, Neuroendocrinology Letters, Current Medical Research and Opinion, Human Psychopharmacology, the Annals of Pharmacotherapy, World Journal of Biological Psychiatry, International Journal of Clinical Practice and Clinical Schizophrenia and Related Psychoses.

Biography Updated on 16 August 2011

Scholarly Contributions [Data Provided by ]